阿司匹林在低危无菌性翻修全髋关节置换术中预防静脉血栓栓塞不劣于其他抗凝药
本研究基于行政数据库比较无菌性翻修全髋关节置换术后阿司匹林与其他抗凝药预防静脉血栓栓塞的效果,经倾向评分匹配获得2,031对患者。结果显示阿司匹林组90天深静脉血栓、肺栓塞和静脉血栓栓塞发生率均更低,输血率无差异,提示阿司匹林是安全有效的非劣效选择。
要点
- 阿司匹林组90天深静脉血栓发生率0.4%低于非阿司匹林组1.6%。
- 阿司匹林组90天肺栓塞0.5%和静脉血栓栓塞0.6%均低于非阿司匹林组。
- 两组30天和90天输血率相似,阿司匹林未增加出血风险。
核心结论
- 在适当选择的低危无菌性翻修全髋关节置换患者中,阿司匹林预防静脉血栓栓塞安全、有效且不劣于其他抗凝药。
研究设计与样本
- 回顾性队列研究,纳入2016至2023年行政数据库中无菌性翻修全髋关节置换患者,排除感染、假体周围骨折、既往静脉血栓栓塞、凝血病或术前抗凝者,经1:1倾向评分匹配后获得2,031对患者。
主要发现
- 阿司匹林组90天深静脉血栓发生率0.4%低于非阿司匹林组1.6%(P < 0.001)。
- 阿司匹林组90天肺栓塞发生率0.5%低于非阿司匹林组1.3%(P = 0.012)。
- 阿司匹林组90天静脉血栓栓塞发生率0.6%低于非阿司匹林组2.4%(P < 0.001)。
- 两组30天和90天输血率相似。
- 非阿司匹林组30天内深静脉血栓超声使用率5.0%高于阿司匹林组3.2%(P = 0.006)。
关键数值与推荐
- 阿司匹林组90天深静脉血栓0.4% versus 非阿司匹林组1.6%(P < 0.001)。
- 阿司匹林组90天肺栓塞0.5% versus 非阿司匹林组1.3%(P = 0.012)。
- 阿司匹林组90天静脉血栓栓塞0.6% versus 非阿司匹林组2.4%(P < 0.001)。
- 非阿司匹林组30天内深静脉血栓超声使用率5.0% versus 阿司匹林组3.2%(P = 0.006)。
临床怎么用
- 对于无菌性翻修全髋关节置换术后低危患者,可考虑使用阿司匹林作为静脉血栓栓塞预防方案。
- 阿司匹林预防未增加输血率,但需结合患者个体情况选择。
局限性
- 本研究为基于行政数据库的回顾性研究,可能存在编码偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While aspirin (ASA) has been widely adopted as an effective method for deep vein thrombosis (DVT) prevention following primary total hip arthroplasty (THA), concerns remain with regard to its efficacy in the setting of revision THA (rTHA). This study aimed to compare venous thromboembolism (VTE) and transfusion rates between patients receiving ASA versus nonaspirin (non-ASA) anticoagulation following aseptic rTHA. METHODS: Patients undergoing aseptic rTHA from 2016 to 2023 were identified in an administrative database. Exclusion criteria included infection, periprosthetic fracture, prior VTE, coagulopathy, or preoperative anticoagulant use. Patients were grouped by postoperative prophylaxis: ASA alone versus non-ASA anticoagulants. Groups were mutually exclusive, except for patients who started ASA and switched to anticoagulation after a VTE event, who remained in the ASA group. Propensity score matching (1:1) was performed based on demographics, comorbidities, insurances, hospital stays ≤ one day, years, and Current Procedural Terminology codes, yielding 2,031 matched pairs. Logistic regressions adjusted for Current Procedural Terminology codes. Outcomes included 30- and 90-day DVT, pulmonary embolus, VTE, and transfusion rates. RESULTS: Aspirin was associated with lower 90-day DVT (0.4 versus 1.6%, P < 0.001), pulmonary embolus (0.5 versus 1.3%, P = 0.012), and VTE (0.6 versus 2.4%, P < 0.001). Transfusion rates were similar at both 30 and 90 days. Notably, DVT ultrasound use within 30 days was significantly higher in the non-ASA group (5.0%) than the ASA group (3.2%, P = 0.006). Regressions controlling for either single- or both-component revisions still showed reduced odds of VTE with ASA compared to non-ASA prophylaxis. CONCLUSIONS: Aspirin is a safe, effective, and noninferior option for VTE prophylaxis following aseptic rTHA in appropriately selected patients.
引用
- Kim BI, Suhardi JV, Gausden EB, et al. Aspirin Is Noninferior to Other Anticoagulants in Low-Risk Patients for Venous Thromboembolism Undergoing Aseptic Revision Total Hip Arthroplasty. J Arthroplasty. 2026. PMID: 41936472. doi:10.1016/j.arth.2026.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。